In this article, we talk about the 15 stocks with the biggest hedge fund momentum.On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025. Despite the selling spree, hedge funds maintained solid performance in early 2026, a period characterized by choppy markets and including the worst single-day drop for three major fund strategies since the COVID-19 pandemic.Goldman Sachs Group Inc.’s ...

Zinger Key Point:MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) , a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new phase 1-ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST. MTX240's ...

On February 17, 2026, Rock Springs Capital Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 159,278 shares of Cogent Biosciences (NASDAQ:COGT), an estimated $4.48 million trade based on quarterly average pricing. What happened According to its SEC filing dated February 17, 2026, Rock Springs Capital Management LP reduced its stake in Cogent Biosciences by 159,278 shares during the fourth quarter. The estimated transaction value was $4.48 million, calculated from ...

On February 13, 2026, First Turn Management disclosed a new position in Cogent Biosciences (NASDAQ:COGT), acquiring 824,283 shares worth $29.28 million at quarter’s end. What happened According to a recent SEC filing dated February 13, 2026, First Turn Management disclosed a new purchase of 824,283 shares of Cogent Biosciences. The fund reported the new position at quarter end, with the value reflecting both the initial investment and any market price changes during the period. What else to know This ...

Product Development and Regulatory Approval - The company is highly dependent on the success of the bezuclastinib program and its ability to discover and develop additional product candidates [195]. - The first New Drug Application (NDA) for NonAdvSM was submitted in 2025, with NDA submissions for GIST expected to be completed by April 2026, and plans to submit an NDA for AdvSM in the first half of 2026 [196]. - The company is building a pipeline of other product candidates, which will require substantial additional funding and is subject to inherent risks of failure in medical product development [197]. - The commercial success of bezuclastinib will depend on market acceptance by physicians, patients, and payors, influenced by the efficacy and safety compared to alternative treatments [203]. - The company plans to seek regulatory approval for bezuclastinib internationally, facing additional risks and regulatory requirements [207]. - The FDA has accepted the company's NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the RTOR program [234]. - The FDA regulatory approval process is lengthy and may cause significant delays in clinical development and marketing approval of product candidates [235]. - Regulatory authorities may require additional clinical trials before granting approval, which could delay commercialization [240]. - The company may face increased product development costs due to unforeseen events during clinical trials [237]. - The company may need to create or obtain companion diagnostics for clinical trials, which is time-consuming and costly [237]. - The development of companion diagnostic tests is critical for realizing the full commercial potential of drug candidates, and delays could adversely affect their development [259]. Competition and Market Risks - The company faces significant competition from major pharmaceutical and biotechnology companies, which may adversely affect its operating results [198]. - The market opportunity for bezuclastinib may be smaller than estimated, impacting revenue potential and profitability [201]. - Insurance coverage and reimbursement for bezuclastinib are uncertain, which could limit marketing capabilities and revenue generation [204]. - The impact of healthcare legislation, such as the Inflation Reduction Act of 2022, could adversely affect the company's revenue prospects [254]. - The company may face challenges in obtaining regulatory approvals in international markets, which could limit market potential [241]. Financial Condition and Funding - The company has incurred net losses since its inception in March 2014 and anticipates continuing to incur losses in the future [293]. - The company may require significant additional funding to support the commercialization of its product candidates and ongoing operations [296]. - As of December 31, 2025, approximately $73.0 million and $1.5 million of federal and state net operating losses are subject to annual limitations due to ownership changes [298]. - The company had cash, cash equivalents, and marketable securities of $900.8 million as of December 31, 2025, compared to $287.1 million as of December 31, 2024 [418]. - The company may face liquidity issues if it cannot generate sufficient cash flow to service its debt obligations, which could lead to asset sales or restructuring [308]. - Adverse legislative or regulatory tax changes could negatively impact the company's financial condition [300]. Intellectual Property and Legal Risks - The company relies on a combination of patents and trade secret protection to safeguard its intellectual property, and any misappropriation could erode its competitive position [261]. - The company has patents issued in multiple territories and anticipates filing additional patent applications, but there is no guarantee of meaningful protection [262]. - Third-party claims of intellectual property infringement could delay product development and commercialization efforts, potentially resulting in substantial damages [267]. - The company may face significant litigation expenses and resource diversion in defending against patent infringement claims, which could harm its business [270]. Operational Challenges - The company may face difficulties in patient enrollment for clinical trials, which could delay development and increase costs [214]. - The company relies on third-party manufacturers for drug candidate production, increasing the risk of supply issues that could impair development efforts [225]. - The API and drug product for bezuclastinib are currently supplied by single-source suppliers, posing a risk to the company's ability to meet clinical testing needs [229]. - The company does not have long-term supply agreements with contract manufacturers, which could lead to challenges in securing necessary drug supplies [226]. - Collaborations and strategic alliances may not yield expected benefits and could involve significant costs and management disruptions [218]. - The company is highly dependent on key personnel, and the loss of any executive officers could delay product development [283]. - The company may rely on third parties for clinical trials and marketing, which could impact its ability to commercialize products effectively [287]. - The company must invest significant resources to develop its internal sales, marketing, and distribution capabilities for future product candidates [289]. Employee and Growth Management - The company increased its headcount from 164 to 258 full-time employees over the past two years to support research, development, and commercial capabilities [285]. - The company plans to build an internal commercial organization for the launch of bezuclastinib, expecting to add up to 100 additional employees [285]. - The company may face challenges in managing growth and recruiting qualified personnel to support its expansion [286]. Risk Management and Compliance - The company maintains cyber insurance, but cannot assure that it will be sufficient to cover all claims related to security breaches [292]. - There is a risk of employee misconduct or noncompliance with regulatory standards, which could significantly impact the business if actions are instituted against the company [256]. - The company is not classified as a covered entity under HIPAA, but could face substantial criminal penalties if it knowingly receives identifiable health information without compliance [257]. - The company may need to expend significant resources to ensure compliance with privacy and data security laws, which could result in adverse publicity and harm the business [258]. - Regulatory compliance failures by third-party manufacturers could result in significant sanctions and adversely affect product supplies [228]. Market and Stock Performance - The trading price of the company's common stock is likely to be highly volatile, influenced by various market factors [301]. - Future sales of common stock may result in dilution of existing stockholders' ownership [304]. - The conditional conversion feature of the Notes may require the company to settle conversion obligations in cash, potentially affecting liquidity [312]. - The accounting treatment of the Notes may lead to lower reported income due to the amortization of issuance costs as a debt discount [315]. - The conversion of the Notes could dilute existing stockholders' ownership interests if settled with shares of common stock [313]. - The company's ability to refinance future indebtedness will depend on capital market conditions and its financial health at that time [308].

Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results WALTHAM, Mass. and BOULDER, Colo., February 17, 2026 -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2025. "Following three positive pivotal trials in 2025, we have entered 2026 with tremen ...

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial position with $9 ...

Core Insights - Cogent Biosciences, Inc. is set to present multiple posters on bezuclastinib results from the SUMMIT trial for NonAdvanced Systemic Mastocytosis at the 2026 AAAAI Annual Meeting [1][2] Group 1: Upcoming Presentations - The posters will cover various aspects of bezuclastinib, including expanded results from the Phase 2 SUMMIT trial, evaluation of bone formation marker changes, patient experiences, symptom burden improvement, and results in subgroups with unmet needs [3] Group 2: Drug Development and Regulatory Status - In December 2025, Cogent submitted a New Drug Application for bezuclastinib to the FDA, based on positive clinical data from the SUMMIT trial and following its Breakthrough Therapy Designation [2] - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is significant in systemic mastocytosis and other related conditions [4] Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases and has an ongoing Phase 1 study of a novel FGFR2/3 inhibitor [4][5]

Core Insights - A significant insider sale of 3,500,000 shares by Fairmount Funds Management LLC occurred despite Cogent Biosciences achieving its best annual performance in 2025, raising questions about the motivations behind the sale [1][6]. Transaction Summary - Fairmount Funds Management LLC sold 3,500,000 shares for approximately $127.4 million, reducing its indirect holdings by 38.87% to 5,503,418 shares [2][3]. - The shares were sold at a reported price of $36.40, which was lower than the closing price of $39.53 on the same day [3]. Company Overview - Cogent Biosciences, based in Massachusetts, is a clinical-stage biotechnology company focused on targeted therapies for rare, genetically driven diseases, with a market capitalization of $5.46 billion and a net income of -$294.37 million [4][5]. - The company's stock experienced a remarkable 286.13% price increase over the past year, with a notable rise of approximately 342% in 2025 [4][6]. Investor Implications - The sale of shares by Fairmount Funds Management, which generated over $120 million, may indicate profit-taking following substantial stock gains, although the specific motivations remain unclear [6]. - Fairmount Funds continues to hold approximately 67,414 units of Series A Convertible Preferred Stock, which could convert to about 16.85 million common shares, subject to ownership limits [7][8].

Core Insights - Pfizer Inc. shares are experiencing an increase due to a price forecast raise by Cantor Fitzgerald from $24 to $27, despite a decline in the broader healthcare sector [1] Recent Developments Supporting Pfizer - Pfizer has entered a non-exclusive licensing agreement with Novavax Inc. for the Matrix-M adjuvant technology, which includes a $30 million upfront payment and potential milestones totaling up to $500 million [2] - Pfizer's drug Sutent, used for gastrointestinal stromal tumors, has received FDA Breakthrough Therapy Designation in combination with Cogent Biosciences' bezuclastinib, showing a 50% reduction in disease progression risk [3] Leadership Commentary - Pfizer CEO Albert Bourla highlighted at the World Economic Forum that reduced funding for U.S. universities is weakening America's position in global health research, with Chinese institutions now holding about 80% of top-tier positions in health research rankings [4] Earnings & Analyst Outlook - Investors are anticipating the next earnings report scheduled for February 3 [5] Benzinga Edge Rankings - Pfizer shares were up 2.14% at $26.43, with an EPS estimate of $0.57 (down from $0.63 YoY) and a revenue estimate of $16.83 billion (down from $17.76 billion YoY) [6] - The company has a P/E ratio of 15.0x, indicating fair valuation, and is trading at a premium relative to peers with a value score of 34.84 [6] - The balance sheet remains healthy with a quality score of 54.07, but the stock is underperforming the broader market with a momentum score of 29.54 [6]